TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05037591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
Study: NCT05497102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Description: Lenalidomide maintenance after carfilzomib, lenalidomide, and dexamethasone re-induction followed by the 2nd ASCT.
Study: NCT06411886

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allergen challenge
Description: Inhaled allergen

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Saline challenge
Description: Inhaled saline
Study: NCT05037591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
Study: NCT05480215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala Device
Description: transcutaneous afferent patterned stimulation (TAPS)
Study: NCT05037591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.
Study: NCT04950712

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples for HSV-2 testing and for HIV test are collected from patients at screening visit (first visit).

Intervention type: PROCEDURE
Intervention: Anogenital lesion swab collection
Description: Anogenital lesion swab of all lesions are collected at screening visit (only for newly infected HSV-2 patients) and at first genital HSV-2 recurrence during the study period.
Study: NCT05108454

Intervention type: DRUG
Intervention: Multiple micronutrient supplementation
Description: Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
Study: NCT05627011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Pediatric Obesity Practice Using Prompts (iPOP-UP)
Description: EHR-based CDS tools refined through a formative evaluation and user-centered design process that immediately preceded this study.
Study: NCT05550870

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raw fenugreek seed powder
Description: It will be given to group 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Roasted fenugreek seed powder
Description: It will be given to group 2
Study: NCT06116539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Description: In the test group, a cyanoacrylate-based tissue adhesive (PeriAcryl 90 HV; Glustitch, Delta, Canada) will be applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: After harvesting the full-thickness connective tissue graft, the edges of the control group will be approximated with 4/0 non-absorbable monofilament nylon suture (Aragó, Barcelona, Spain).
Study: NCT05311449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The experimental group will start with LI4 points, and continue with P6 and SP6 points. The application will be carried out by determining the priority order of the points with the draw. Attention will be paid to the intensity and duration of the pressure deemed appropriate. Since the individuals' responses will differ, the stiffness and pressure will be adjusted according to the individual's sensitivity not to cause tissue damage. Before starting the application, around the area to be pressed for 20-30 seconds will be gently rubbed with palm. With the gentle rubbing of the surrounding tissue, the tension and tissue sensitivity in warming, relaxing and preparatory will be reduced, and the tissue will be relieved. After, the point determined will be pressed manually for 2 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo acupressure
Description: In the control group, the application will start with the points 1.5 cm around the LI4, P6 and SP6 points. The application process will continue in the same way with acupressure group and the pressure intensity will be less.
Study: NCT06404866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMotion
Description: Participants will complete one lesson per week. The weekly education is targeted to women and contains personalized content via a variety of diverse lesson narratives. Each week participants listen to scripted sessions they can complete on their own time regarding each of the weekly topics (lasting about 30 minutes). At the end of the week, they then meet individually with a study team member virtually to discuss the same subject.
Study: NCT05037591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sea grapes extract 1.68 g/70kg BW
Description: Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).
Study: NCT05842044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg Acetaminophen administered orally during preoperative period. Standardized regimen of Acetaminophen administered during post-surgery (inpatient) period, during postoperative follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization.
Study: NCT05037591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).
Study: NCT05577312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRL-101
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
Study: NCT05410171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: early warning platform
Description: High risk inpatients will be evaluated by early warning platform
Study: NCT06132425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure
Description: All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: All participants complete two study visits, each consisting of 8 exposure trials for durations of 1 minute each, resulting in a total of 16 exposures. For each exposure, participants are assigned a speech topic and given 1 minute to give an unprepared speech to two study confederates.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehearsal
Description: After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehearsal
Description: After every two exposures, participants will complete a rehearsal task where the participant is asked to use a positive or neutral approach to remember and recount the exposures they have just completed.
Study: NCT05037591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).
Study: NCT04812119

Intervention type: DIAGNOSTIC_TEST
Intervention: The Visual Function Classification System (VFCS)
Description: The Visual Function Classification System (Baranello et al, 2019) is a valid and reliable 5-level classification system of visual functioning for children with Cerebral Palsy. It describes the use of visual abilities in daily life, focusing on activity and participation.
Study: NCT05842044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Standardized regimen of Oxycodone administered orally (PO) on demand for moderate pain during post-surgery (inpatient) period.~At discharge 5mg Oxycodone will be administered to participants on demand if pain score is greater than 7, or if participant required greater than 25mg Oxycodone during the hospitalization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.
Study: NCT04812119

Intervention type: DIAGNOSTIC_TEST
Intervention: The Early Childhood Oral Health Impact Scale (ECOHIS)
Description: The ECOHIS measures the impact of oral problems and/or experience of dental treatment on the quality of life in children under 5 years old and their parents or other family members. It has 13 questions divided into two domains: one related to impact on the child (9 questions), and another to impact on the family (4 questions), measured using the Likert scale. In children with cerebral palsy and/or the ECOHIS has been validated for ages up to 6,5 years, in children with intellectual disability for ages up to 5 years and in children with special need for ages up to 9 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Family Impact Scale (FIS)
Description: The FIS evaluates the impact of a child's oral condition on family life. It consists of 14 items divided into three subscales: parental/family activity (PA), parental emotions (PE), and family conflict (FC). The financial burden subscale (FB) is the only one that is evaluated separately, since it comprises a single item and addresses economic rather than psychosocial or behavioural impact. It has been validated for children above the age of 12 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: The Achenbach System of Empirically Based Assessment (ASEBA)
Description: The Achenbach System of Empirically Based Assessment (ASEBA; Achenbach) is a collection of questionnaires used to assess adaptive and maladaptive behavior and overall functioning in individuals. The system includes report forms for multiple informants - the Child Behavior Checklist (CBCL) is used for caregivers to fill out ratings of their child's behavior, the Youth Self Report Form (YSR) is used for children to rate their own behavior, and the Teacher Report Form (TRF) is used for teachers to rate their pupil's behavior. The ASEBA seeks to capture consistencies or variations in behavior across different situations and with different interaction partners. The ASEBA exists for multiple age groups, including preschool-aged children, school-aged children, adults, and older adults. Scores for individuals in each age group are norm-referenced.

Intervention type: DIAGNOSTIC_TEST
Intervention: Adaptive Behavior Assessment System Third Edition (ABAS-3)
Description: The ABAS-3 (Harrison, Oakland, 2015) is a rating scale useful for assessing skills of daily living in individuals with developmental delays, autism spectrum disorder, intellectual disability, learning disabilities, neuropsychological disorders, and sensory or physical impairments. Rating forms are filled out by the parent and a teacher. The ABAS-3 covers three broad domains: conceptual, social, and practical, using 11 skill areas within these domains. Tasks focus on everyday activities required to function, meet environmental demands, care for oneself, and interact with others effectively and independently. On a 4-point response scale, raters indicate whether, and how frequently, the individual performs each activity.
Study: NCT05058573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group (n=22)
Description: Control group will be received only medical treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group (n=22)
Description: Control group will be received only medical treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group (n=22)
Description: Control group will be received only medical treatment
Study: NCT05594121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Subcutaneous Buprenorphine
Description: Monthly subcutaneous injections of long-acting buprenorphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Sublingual Buprenorphine
Description: Daily sublingual fast-acting buprenorphine
Study: NCT05842044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Standardized regimen of Hydromorphone administered intravenously (IV) on demand for severe pain during post-surgery (inpatient) period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg Ibuprofen tablets administered orally (PO) every eight (8) hours for 5 days.
Study: NCT06066294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regimen 1
Description: WHO Pre-qualified rabies vaccine (Rabivax-S), WHO recommended PrEP Vaccination Schedule, 2 visits, 0.2ml 2 sites (0.1ml each site) on day 0 and day 7

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Regimen 2
Description: WHO Pre-qualified rabies vaccine (Rabivax-S), Government of India approved vaccination schedule, 3 visits, 0.1ml 1 site on day 0, 7 and 28
Study: NCT04667754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy
Description: ICBT provides online structured self-help modules over several months based on the principles of CBT in combination with weekly guidance through emails and telephone calls. The course comprises 6 online lessons that provide psychoeducation about: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure/pacing; 5) memory and attention; and 6) relapse prevention. Participants will also have the opportunity to ask any questions regarding the content of the program materials and will receive a response from their Guide within 48-72 hours. Guide will spend \~15 mins. per week/per participant. All Guides have completed a university program (psychology or social work) and are registered clinicians or students working under supervision of a registered clinician.
Study: NCT05037591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).
Study: NCT04640493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: If patients have been diagnosed with SDB using the WatchPat device, they will start dapagliflozin. Repeat WatchPat SDB assessment will be performed after 3 and 6 months of continuous dapagliflozin therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WatchPat
Description: HF patients undergo SDB testing with the WatchPat device. (non-experimental)
Study: NCT05037591

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lactose powder (1.68 g/70kg BW day-1).
Study: NCT06248632

Intervention type: OTHER
Intervention: Expression of inflammatory markers (Il6, Il8, Il1β, CXCL1, CCL2, CXCR3, Il1R, Il6R)
Description: Expression of inflammatory markers obtained from circulating monocytic cells of XLH
Study: NCT04782050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound liver assessment
Description: The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
Study: NCT06441071

Intervention type: PROCEDURE
Group type: OTHER
Intervention: position
Description: Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: position
Description: Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.
Study: NCT06163300

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI advanced techniques
Description: Participants will be submitted to MRI studies at diagnosis, during disease evolution and after treatment. Data collected will be analysed by two different neuroradiologists using advanced techniques.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI advanced techniques
Description: Participants will be submitted to MRI studies at diagnosis, during disease evolution and after treatment. Data collected will be analysed by two different neuroradiologists using advanced techniques.
Study: NCT05407272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education Manual
Description: A health education manual based on a shared model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual
Description: routine care
Study: NCT06441071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: position
Description: Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: position
Description: Patients undergoing Video-assisted Thoracoscopic Surgery were selected for the study, and nerve block was performed before surgery, followed by holding different positions for 30 min, after which the effect of the block was measured.